Oral Urea Clinical Indications
Oral urea has two distinct clinical uses: treating hyponatremia due to SIADH (syndrome of inappropriate antidiuretic hormone secretion) and serving as a topical dermatological agent for hyperkeratotic skin conditions.
Primary Indication: SIADH-Related Hyponatremia
Oral urea is an effective treatment for euvolemic hyponatremia caused by SIADH, with robust evidence supporting its use in both acute and chronic settings 1, 2.
Efficacy Profile
- Increases serum sodium by approximately 9-10 mmol/L overall, with effects visible within 24 hours (mean increase of 4.9 mmol/L) 1, 2
- More effective in severe hyponatremia: Patients with sodium <120 mEq/L show greater increases (18 mmol/L) compared to moderate (7.9 mmol/L) or mild cases (8 mmol/L) 1
- Comparable efficacy to fluid restriction and vaptans, but superior to no treatment 1
When to Use Oral Urea for SIADH
Use oral urea in patients with:
- Chronic SIADH-related hyponatremia requiring long-term management 3
- Mild to moderate acute hyponatremia where rapid correction is not urgently needed 4
- Resource-limited settings where vaptans are unavailable or unaffordable 1
- Contraindications to other therapies or when fluid restriction fails 3
Dosing and Duration
While specific dosing protocols vary across studies, typical treatment duration is 5-7 days for acute cases, with longer-term use for chronic SIADH 2. The median treatment duration in systematic reviews was 5 days 2.
Safety Considerations
Oral urea is remarkably safe with minimal adverse effects 1, 2:
- Most common side effect: poor palatability/dysgeusia (bad taste)
- No cases of osmotic demyelination syndrome (ODS) reported in systematic reviews 2
- Experimental data suggests urea may actually protect against ODS 3
- No systemic toxicity observed
Important Caveat
The evidence base consists entirely of observational studies with no randomized controlled trials, resulting in low-quality evidence by GRADE criteria 4. However, the consistent positive findings across multiple studies and excellent safety profile support its clinical use, particularly when other options are limited or contraindicated.
Secondary Indication: Dermatological Conditions (Topical Use)
Note: The FDA-approved formulations are topical preparations, not oral 5.
Topical urea (typically 20% cream) is indicated for 5:
- Hyperkeratotic conditions (dry, rough skin)
- Psoriasis, xerosis, ichthyosis, eczema
- Keratosis pilaris, corns, calluses
- Dermatitis and atopic dermatitis
- Damaged or ingrown nails
- Onychomycosis (as adjunctive therapy)
The mechanism involves dissolving intercellular matrix, loosening the horny skin layer, and promoting shedding of scaly skin 5, 6.
Not for Hyperammonemia Management
While the guideline evidence discusses urea cycle disorders and hyperammonemia management, oral urea is NOT used to treat hyperammonemia 7. The guideline focuses on nitrogen-scavenger medications (sodium benzoate, sodium phenylacetate) and dialysis for acute hyperammonemia, not urea supplementation.